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Abstract
The generation of an immune response can dramatically alter the circulation lifetime of a targeted liposome, particularly
when the response is generated against the surface-coupled ligand. Following repeated administrations, rapid elimination of
the carrier system is observed, thereby limiting potential applications for targeted liposomes in a therapeutic setting. In this
study, we have investigated whether the encapsulation of a toxic drug within the carrier could prevent an immune response
against a surface-bound protein. Liposome clearance and humoral immune response were monitored throughout multiple
administrations of liposomes containing doxorubicin with surface-conjugated ovalbumin. The results show that low doses of
encapsulated doxorubicin can prevent humoral immunity against repeated administration of liposomes conjugated with
ovalbumin. The immunosuppressive effect was specific for the ovalbumin coupled to the liposome surface. This selective
suppression of immunity against a surface conjugated protein could prove advantageous for safe repeated administration of
protein containing liposomal systems. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The newest generation of liposomal drug-delivery
systems has focused on delivery to speci¢c target cells
through the use of antibodies and other ligands
coupled to the membrane surface. The earliest tech-
niques used to couple antibodies to liposomes re-
sulted in rapidly cleared, unstable formulations [1,2].
The subsequent addition of PEG-polymers improved
stability and reduced the RES uptake of targeted
systems [3], unfortunately, the addition of PEG can
also interfere with the binding of ligands to their
target receptors [4,5]. Despite these di⁄culties, lipo-
somes and their contents have been successfully de-
livered to the target cell population both in vitro and
in vivo [6^9].
One of the major remaining obstacles in the appli-
cation of targeted liposome-delivery systems con-
cerns immune responses to the surface-coupled mol-
ecules. The natural adjuvant property of liposomes
has been recognized since the 1970s [10], with the
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most signi¢cant humoral immune response generated
against vesicles with protein covalently coupled to
the surface [11,12]. The generation of a humoral im-
mune response will result in the rapid elimination of
these targeted drug-delivery systems after the ¢rst
administration. Without the potential for multiple
administrations, targeted drug-delivery systems will
be of limited value in the treatment of disease. En-
capsulation of cytotoxic drugs (such as the anti-
cancer drug, doxorubicin), has been suggested as a
possible solution to inhibit immune responses gener-
ated against surface-coupled molecules. These agents
have been shown to interfere with antigen processing
and presentation [13^15]. The role of the macro-
phage in the generation of an immune response to
liposomal antigens has been well documented [16^
18], and liposomal doxorubicin is known to be an
inhibitor of liver Kup¡er cell and splenic macro-
phage activity [19,20]. The administration of liposo-
mal doxorubicin should therefore directly inhibit im-
mune responses mediated by these cells. Additional
evidence has documented direct interactions between
liposomal surface proteins and antigen-speci¢c lym-
phocyte subpopulations [13,17,21^24], providing a
potentially more e⁄cient route for the suppression
of the immune response. The primary objective of
these experiments was to characterize the dose limi-
tations and possible antigen selectivity of the immune
suppression induced by doxorubicin encapsulated
within liposomes with surface-associated protein.
2. Materials and methods
2.1. Materials
DSPC (1,2-distearoyl-sn-glycero-3-phosphocho-
line) and MPB-DSPE (N-(4-(P-maleimidophenyl) bu-
tyryl) distearoyl phosphatidylethanolamine) were
purchased from Northern Lipids (Vancouver, BC).
PEG-DSPE was generously provided by Dr. Steven
Ansell of Inex Pharmaceuticals (Vancouver, BC).
Lipid marker, [3H]cholesteryl hexadecyl ether
(CHE) was purchased from NEN, Mississauga,
ON. Doxorubicin was obtained from Adrian Labo-
ratories. Imject Ovalbumin, biotinylated goat anti-
mouse IgG, and streptavidin-linked L-galactosidase
were purchased from Pierce (Rockford, IL). Female
CD-1 mice were obtained from Charles River (St.
Constant, PQ). Cholesterol (Chol), SPDP (N-succini-
midyl 2-(2-pyridyldithio) propionate), dithiothreitol
(DTT), HEPES (N-2-hydroxyethylpiperazine-N-2-
ethane-sulfonic acid), citrate, CL-4B Sepharose, G-
50 Sephadex, hen egg lysozyme (HEL), bovine serum
albumin and most other chemicals were purchased
from Sigma (St. Louis, MO).
2.2. Preparation of liposomes
Large unilamellar vesicles (LUVs) were prepared
at various concentrations by extrusion of freeze^
thawed multilamellar vesicles through two stacked
100-nm polycarbonate ¢lters (Nucleopore, Pleasan-
ton, CA) using an extrusion device (Lipex Biomem-
branes, Vancouver, BC) [25]. DSPC/Chol (55:45,
mol%) and DSPC/Chol/DSPE-PEG2000/MPB-DSPE
(52:45:2:1, mol%) liposomes were prepared in
HEPES bu¡ered saline solution (HBS; 20 mM
HEPES, pH 7.4, 145 mM NaCl) at 2^200 mM total
lipid concentrations. The average size of these lipo-
somes was 100 þ 30 nm as determined by quasielastic
light-scattering analysis (QLS) using a Nicomp Mod-
el 270 Submicron Particle Sizer (Nicomp Instru-
ments, Santa Barbara, CA). Liposomes were radio-
labelled using a lipid marker, [3H]cholesteryl
hexadecyl ether (CHE) (NEN, Mississauga, ON).
When used for biodistribution, liposomes contained
1 WCi [3H]CHE/3 Wmol of total lipid. For all other
samples, a trace amount of this label (0.01 WCi/Wmol)
was used to monitor changes in lipid concentration.
This label is non-exchangeable and non-metaboliz-
able due to low levels of cholesteryl ester transfer
protein activity [26^28], and this label has been
shown to be similarly stable in CD-1 mice (P.R.
Cullis et al., unpublished results). Speci¢c activities
of liposome preparations were determined by stand-
ard liquid scintillation counting methods using a
Beckman LS 3801 Liquid Scintillation System (Beck-
man Instruments, Fullerton, CA), and a colorimetric
phosphorous assay [29]. When a pH gradient was
required for drug-loading, the liposomes were pre-
pared in 300 mM citrate (pH 4.0) and the external
bu¡er exchanged with HEPES-bu¡ered saline solu-
tion (HBS; 20 mM HEPES, pH 7.5, 145 mM NaCl)
by gel ¢ltration on pre-packed Sephadex G-25 mini-
columns (PD-10 columns) (Pierce, Rockford, IL).
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2.3. Protein coupling to liposomes
Imject ovalbumin (10 mg/ml in 0.9% saline) was
modi¢ed with the amine cross-linker SPDP as de-
scribed previously by Loughrey et al. [30,31]. Oval-
bumin was selected because of its immunogenicity,
possesses well-studied antigenic epitopes and immune
response behavior, and has been prepared in a puri-
¢ed, stable form ideal for the coupling procedure
used. Brie£y, SPDP was dissolved in ethanol and
diluted with HBS just prior to addition to the oval-
bumin solution in a 5-fold molar excess. After 30 min
at room temperature, the unreacted SPDP was re-
moved using a G-50 Sephadex column equilibrated
with HBS (pH 7.5) and then reduced for 30 min with
25 mM DTT. The activated ovalbumin was isolated
on a G-50 Sephadex column just prior to coupling to
MPB-DSPE containing liposomes at a ratio of 90 Wg
protein/Wmol lipid (15 mM ¢nal lipid concentration),
for 18 h at room temperature under nitrogen. Un-
conjugated ovalbumin was separated from protein-
coupled liposomes by passage down a Sepharose
CL-4B column (HBS, pH 7.5). Quanti¢cation of
ovalbumin coupling was carried out using the Pierce
Micro BCA protein assay in the presence of 1% Tri-
ton X-100 to disrupt the liposomes. The ovalbumin
coupling procedure consistently resulted in 30^40 Wg
protein/Wmol lipid. Coupling of HEL followed the
same procedures outlined above and consistently
produced approximately 40 Wg protein/Wmol lipid.
HEL was chosen due to its highly antigenic nature
and well-studied immunogenic behavior of the pro-
tein in animal systems.
2.4. pH gradient doxorubicin encapsulation
Doxorubicin was encapsulated in selected formu-
lations using a transmembrane pH gradient as pre-
viously described by Mayer et al. [32^34]. Ovalbu-
min-coupled liposomes with an internal pH of 4.0
(citrate bu¡er) and an external pH of 7.5 (HBS)
were heated to 65‡C and then mixed with a doxoru-
bicin solution for 10 min (10 mg/ml in 0.9% saline,
65‡C). This procedure results in s 95% trapping
e⁄ciencies, eliminating the need to separate free
doxorubicin [33]. Drug-to-lipid molar ratios ranging
from 0.03 to 0.2 were generated in these studies.
For ovalbumin^liposome formulations not requiring
doxorubicin, a mock loading procedure was carried
out using a drug-free 0.9% saline solution.
2.5. In vivo mouse biodistribution studies
Liposome formulations (200 Wl) were administered
via the lateral tail vein of female CD-1 mice. Lipid
doses (except where speci¢ed in ¢gure legends) con-
tained 50 Wg of coupled protein, equivalent to a lipid
dose of approximately 45 mg lipid/kg body weight
and a doxorubicin dose of 8 mg/kg. All time points
were taken 4 h after the designated injections, with
mice being sacri¢ced by exposure to carbon dioxide.
Blood was removed by cardiac puncture, collected in
EDTA-coated plasma collection tubes (Bectin
Dickinsen, Franklin Lakes, NJ) and centrifuged at
3000 rpm for 5 min to isolate the plasma fraction.
Plasma liposome concentrations were determined
from the speci¢c activity of the injected liposomes,
using standard liquid scintillation counting tech-
niques. Plasma volume was assumed to be 5% the
total body weight. All in vivo analyses used four
mice per time point, and the standard error of the
mean to represent variability of results.
2.6. Immunization studies with ovalbumin-coupled
liposomes
All immunization experiments used liposome for-
mulations as described above, with samples contain-
ing [3H]CHE only when monitoring biodistributions.
Unless otherwise designated in ¢gure legends, mice
were injected i.v. with speci¢ed formulations for
2 consecutive weeks (primary and secondary stimu-
lation). Plasma elimination studies examined the bio-
distribution of the second weekly injection at the 4-h
timepoint. Immune response to the coupled protein
was determined by ELISA detection of antigen-spe-
ci¢c IgG, 7 days after the second weekly injection.
Additional experiments on the prevention, speci¢city,
or elimination of immune response used procedures
outlined above with the dosing and injection sched-
ules described within the ¢gure legends.
2.7. ELISA assay for antigen-speci¢c immunoglobulin
Micro-assay plates (Bectin Dickinson, Franklin
Lakes, NJ) were coated with ovalbumin (50 Wl/well
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of 40 Wg/ml) and incubated at 4‡C overnight (HEL
replaced ovalbumin in the speci¢city study examining
anti-HEL antibody production). The plates were
washed twice with PBS^Tween 20 (phosphate-bu¡-
ered saline, Ca2 and Mg2 free, 0.1% (v/v) Tween
20), before blocking for 1 h with 2% bovine serum
albumin (in PBS) at 37‡C. After rinsing with PBS^
Tween 20 and then 1% BSA (in PBS), 100 Wl of
plasma diluted in PBS was allowed to incubate at
room temperature for 1 h. Plates were subsequently
rinsed three times with PBS^Tween 20, before addi-
tion of 100 Wl aliquots of 0.5 Wg/ml biotinylated goat
anti-mouse IgG (1% BSA, PBS)(30 min, room tem-
perature). Plates were again rinsed three times with
PBS^Tween 20, before addition of 100 Wl of 500 mU/
ml of streptavidin-linked L-galactosidase (1% BSA,
PBS) (30 min, room temperature). Plate-associated
L-galactosidase was quanti¢ed by the addition of
100 Wl CPRG (chlorophenol red-L-D-galactopyrano-
side) at a concentration of 2 mg/ml. After 20 min, the
production of chlorophenol red was monitored by
determining the absorbance (relative to controls) at
570 nm on a Titertek Multiscan plate reader (Titer-
tek Instruments, Huntsville, AL). Controls consisted
of plasma from untreated female CD-1 mice.
3. Results
3.1. Entrapped doxorubicin eliminates the humoral
immune response against liposomal ovalbumin
Investigations using liposomes with surface-bound
molecules have revealed the generation of humoral
immunity. In the experiments presented here, we use
liposomes coupled to the highly immunogenic pro-
tein ovalbumin to study the e¡ects of cytotoxic
drugs, such as doxorubicin, on this immune re-
sponse. This ‘proteoliposome’ model system will as-
sist us in identifying potential immune-response
problems associated with targeted liposomes contain-
ing similar cytotoxic drugs.
When empty ovalbumin proteoliposomes are ad-
ministered i.v., a signi¢cant immune response is gen-
erated, resulting in the rapid elimination of subse-
quent injections (Fig. 1A). During the second and
third administrations, the proteoliposomes were
completely cleared from the blood, predominantly
by the organs of the RES, before the 4-h timepoint.
Rapid removal of the carrier was also observed for
proteoliposome doses as low as 5 Wg conjugated
ovalbumin/900 Wg lipid (results not shown). The pro-
Fig. 1. Dose titration of ovalbumin^proteoliposomes with and without entrapped doxorubicin. Female CD-1 mice were injected i.v.
for three consecutive weeks with ovalbumin-coupled liposomes (50 Wg of protein/900 Wg lipid). Formulations were either empty or
contained doxorubicin encapsulated at a 0.2 drug-to-lipid ratio (mol/mol), producing a maximum lipid dose of 45 mg/kg containing
8 mg/kg of drug. (A) Plasma levels of injected lipid 4 h after weekly injections. Scintillation counting was used to detect the radiola-
belled lipid marker ([3H]CHE) incorporated in the lipid bilayer. (B) The relative production of ovalbumin-speci¢c IgG (absorbance
570 nm) as determined by ELISA assays of plasma isolated 7 days after the second weekly injection. The ovalbumin dosing range
was achieved by injecting various amounts of the same formulation (50 Wg of protein/900 Wg lipid). As such, as the ovalbumin dose
decreases, the total doxorubicin dosage decreases. Solid symbols represent doxorubicin-loaded and open symbols indicate empty lipo-
somes. All data points represent the mean and standard error of four mice. *No measurable plasma lipid.
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duction of ovalbumin-speci¢c IgG correlated with
the rapid elimination of the vesicles from the blood
(Fig. 1B). The results suggest an ‘all-or-none’ humor-
al immune response, with no detectable immune re-
sponse seen only at the 0.5 Wg proteoliposome dose.
Importantly, when rapidly cleared 50 Wg proteolipo-
some formulations contained doxorubicin, it pre-
vented the formation of ovalbumin-speci¢c IgG,
and restored the long circulation lifetimes of subse-
quent injections (Fig. 1A). The total doxorubicin
dosage used to achieve this e¡ect was 8 mg/kg, which
is well below the maximum tolerable dose of 50 mg/
kg for DSPC/Chol-based carriers [33]. When the dose
of doxorubicin loaded ovalbumin-coupled liposomes
was decreased to 6 Wg of ovalbumin, an immune
response was observed. This corresponds to a total
doxorubicin dose of less than 1 mg/kg, suggesting a
threshold level of doxorubicin is required to prevent
the generation of an anti-ovalbumin immune re-
sponse.
3.2. In£uence of drug concentration on the immune
response against liposomal ovalbumin
To determine the role of drug concentration on the
immune response, liposomes containing a range of
drug concentrations were examined. This was
achieved by altering the drug-to-lipid ratio of the
formulation. Preliminary experiments demonstrated
that two injections were su⁄cient to manifest
changes in immune response and liposome behavior,
therefore each subsequent study examined immune
responses following two injections. To determine
the lowest dose at which doxorubicin would elimi-
nate the immune response, mice were injected with
doxorubicin-encapsulated proteoliposomes contain-
ing various drug-to-lipid molar ratios for 2 consec-
utive weeks. The total lipid and protein dose was
kept constant (45 mg lipid/kg body weight, 50 Wg
ovalbumin) so that the decreasing drug-to-lipid ratio
resulted in a decreased total drug dose. The results in
Fig. 2 show that lowering the drug-to-lipid ratio to
0.1 (equal to a 4 mg/kg total drug dose) still success-
fully suppressed the ovalbumin-speci¢c immunity
generated by the second injection (Fig. 2). This re-
sulted in high plasma lipid concentrations for the
second injection (results not shown). At drug-to-lipid
ratios lower than 0.1, an immune response is gener-
ated, resulting in rapid elimination of the carrier
after the second injection.
3.3. In£uence of total doxorubicin dose on the immune
response against liposomal ovalbumin
Results of the previous section indicate that a high
drug-to-lipid ratio results in more e¡ective immune
response suppression. In order to determine the low-
est total drug dose that would result in suppression
of the immune response, we administered two weekly
injections of doxorubicin-proteoliposomes at a con-
stant 0.2 drug-to-lipid ratio, but decreased the total
drug dose by administering a lower lipid dose. Fig. 3
shows that high drug-to-lipid ratio preparations were
more e¡ective at eliminating immune responses than
equivalent doses of doxorubicin encapsulated at low-
er drug-to-lipid ratios (Fig. 2). Only doxorubicin
doses of 1 mg/kg or less failed to suppress the pro-
duction of anti-ovalbumin IgG (Fig. 3). This indi-
cates that delivery of highly concentrated doxorubi-
cin within liposomes (high drug-to-lipid ratios) was
twice as e¡ective at inhibiting antibody production
against the liposomal surface protein compared to
lower drug-to-lipid ratio preparations. This is based
Fig. 2. E¡ect of drug-to-lipid ratio on the generation of an
anti-ovalbumin immune response. Female CD-1 mice were in-
jected i.v. for 2 consecutive weeks with doxorubicin entrapped
in ovalbumin-coupled liposomes at a constant protein and lipid
dose (50 Wg ovalbumin; 45 mg lipid/kg b.wt.). Plasma samples
were isolated 7 days after the second weekly injection for im-
mune response determination. All data points represent the
mean and standard error of four mice.
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on the minimum drug dose required to suppress the
immune response in the above experiments (4 and
2 mg/kg doxorubicin, respectively).
3.4. In£uence of doxorubicin location on the immune
response against liposomal ovalbumin
Liposomal doxorubicin has been shown to elimi-
nate phagocytic cells, which act as antigen-presenting
cells for the surface-coupled proteins [19,20]. This
might result in the inhibition of immune response
by inhibiting the antigen processing and presentation
functions of these cells. The signi¢cant uptake of
liposomes and proteoliposomes by the macrophages
of the liver and spleen [16,17,35,36], suggests that
liposomal doxorubicin could be just as e¡ective as
proteoliposomes containing the drug, as both are
accumulated within these phagocytic cells of the
RES. To test this possibility, mice were injected
with a mixture of liposomal doxorubicin and empty
ovalbumin proteoliposomes. The resulting plasma
elimination and ELISA immune response data indi-
cate that only the highest dose of liposomal doxo-
rubicin (8 mg/kg) prevented the immune response
and rapid elimination of co-administered ovalbumin
proteoliposomes (Fig. 4A,B). This suggests that
although high doses of liposomal doxorubicin could
act generally against phagocytic cells to prevent an
immune response, encapsulation of doxorubicin
within the proteoliposomes was more e¡ective in pre-
venting an immune response against the proteolipo-
some.
Fig. 4. Ovalbumin proteoliposome immune response and plasma elimination when co-injected with liposomal doxorubicin. Female
CD-1 mice were injected i.v. for two consecutive weeks with 50 Wg of empty ovalbumin^liposomes and various doses of 0.2 drug-to-
lipid ratio liposomal doxorubicin (DSPC/Chol/PEG-DSPE; 53:45:2, mol%), up to a maximum drug dose of 8 mg/kg. (A) Plasma lev-
els of ovalbumin^liposomes 4 h after the second weekly injection as determined using standard scintillation counting. (B) The relative
production of ovalbumin-speci¢c IgG (absorbance 570 nm) as determined by ELISA assays of plasma isolated 7 days after the second
weekly injection of each formulation. All data points represent the mean and standard error of four mice.
Fig. 3. E¡ect of total doxorubicin dose on the generation of an
anti-ovalbumin immune response. Female CD-1 mice were in-
jected i.v. for 2 consecutive weeks with various doses of doxo-
rubicin entrapped in ovalbumin-coupled liposomes (50 Wg of
protein/900 Wg lipid). Plasma samples were isolated 7 days after
the second weekly injection for immune response determination.
All data points represent the mean and standard error of four
mice.
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3.5. The antibody response to antigen-associated
liposomes is selectively inhibited by entrapment of
doxorubicin within liposomes
To determine whether the doxorubicin-induced im-
mune suppression was selective for a speci¢c protein
or involved a general blockade of the immune sys-
tem, the humoral immune response to an unrelated
liposomal protein was studied in drug-treated ani-
mals. The humoral response to liposomal HEL was
monitored in animals co-administered with doxoru-
bicin-loaded ovalbumin^liposomes encapsulated at a
0.2 drug-to-lipid ratio. The purpose of the study was
to determine whether the drug-treated mice could
mount an immune response to an unrelated liposo-
mal antigen which did not contain encapsulated
drug. As demonstrated in Fig. 5, doxorubicin doses
as high as 8 mg/kg fail to block the majority of anti-
HEL antibody production against the liposomal
HEL. An inhibition of the humoral response against
liposomal HEL is observed, but an inhibition which
is only partial despite administration of ovalbumin^
liposomes with encapsulated doxorubicin at doses
which successfully blocked the antibody response
(Fig. 2). Comparatively, the antibody response to
ovalbumin was completely blocked when ovalbu-
min^liposomes were co-injected with high dose of
encapsulated doxorubicin (Fig. 4B). Altogether, these
results indicate that the encapsulation of doxorubicin
within a proteoliposome can impart a relatively se-
lective inhibition of some components of the immune
system for the speci¢c protein associated with the
liposome.
4. Discussion
In this study, we observed that the humoral re-
sponse generated against an ovalbumin-coupled lipo-
some could be blocked by the encapsulation of
doxorubicin within the carrier. The extent of this
immune regulation appears to be highly dependent
on the drug-to-lipid ratio of the carrier. We also
observed that the immune suppression is relatively
speci¢c to the protein coupled to the doxorubicin
containing liposomes. This selective immune sup-
pression could be useful for proteoliposome admin-
istrations where multiple dosing schedules are re-
quired.
Repeated injections of ovalbumin^liposomes in-
duce production of antibodies against ovalbumin
which cause subsequent injections to exhibit rapid
elimination from the circulation. As shown in the
dose titration experiments, low doxorubicin doses
can prevent this antibody response. Complete sup-
pression of the ovalbumin immune response could
be achieved with 2 mg/kg doxorubicin administered
at a drug-to-lipid ratio of 0.2:1 (mol:mol) (Fig. 3).
This same dose of doxorubicin encapsulated at lower
drug-to-lipid ratios did not block the production of
ovalbumin antibodies, resulting in rapid elimination
of subsequent injections. These results suggest that
the concentration of doxorubicin within the carrier
is crucial in blocking an immune response against a
surface-coupled protein. When the doxorubicin was
encapsulated in a separate carrier, a drug dose of
8 mg/kg was required to block the immune response.
This is four times the dosage required when the drug
is encapsulated within the same carrier. Macrophages
of the liver and spleen are the predominant cells me-
diating liposome uptake. These cells are also in-
volved in the processing and presentation of liposo-
mal proteins and can be killed or inactivated in vivo
Fig. 5. Immune response to HEL proteoliposomes with simulta-
neous injection of doxorubicin encapsulated within ovalbumin^
liposomes. Female CD-1 mice were co-injected with 50 Wg of
empty HEL^liposomes and varying doses of 0.2 drug-to-lipid
ratio doxorubicin in ovalbumin-coupled liposomes for 2 consec-
utive weeks. The ¢gure shows the relative production of HEL-
speci¢c IgG (absorbance 570 nm) as determined by ELISA as-
says of plasma isolated 7 days after the second weekly injection
of each formulation. All data points represent the mean and
standard error of four mice.
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by liposomal doxorubicin [19,20]. Daemen et al. have
shown that one i.v. injection of 5 mg/kg doxorubicin
in PEG-containing liposomes reduced the phagocytic
capacity of rat liver macrophages by 30% without a
substantial change in the actual number of macro-
phages at 24 h after injection. By 72 h, uptake was
reduced by 65% and a substantial decrease in the
number of macrophages was observed [20]. This is
in contrast to the initial studies of Daemen where
doxorubicin liposomes lacking PEG only decrease
the phagocytic activity of the macrophages. Doxoru-
bicin encapsulated in PEG liposomes (long circulat-
ing liposomes) are taken up slowly compared to con-
ventional liposomes, this explains the delay necessary
to observe both a decrease in the phagocytic activity
as well as numbers of phagocytic cells. According to
these observations, the impaired macrophage uptake
may lead to a diminution of the antibody response
against the linked antigen due to the lack of antigen
presentation. Comparatively, the suppression of the
antibody response against an antigen conjugated to
empty liposomes will require a higher dose of doxo-
rubicin. When the phagocytic activity is partially re-
duced with Dox^liposomes at low doses, liposomes
with covalently linked OVA will access the pool of
macrophages not yet damaged and an immune re-
sponse will occur. It is only at doses where the up-
take is signi¢cantly reduced and the number of se-
verely damaged macrophages is high that we observe
a dramatic inhibition of the anti-OVA humoral re-
sponse. However, the doxorubicin-induced unrespon-
siveness is not simply a consequence of the diminu-
tion of the number of phagocytic cells or reduced
uptake itself ; co-injection of HEL-linked liposomes
with high doses of entrapped doxorubicin within
OVA-linked liposomes did not abolish the anti-
HEL antibody response. The decreased antibody
production observed is not su⁄cient enough to pre-
vent the rapid elimination of HEL^liposomes from
the plasma upon the second injection (data not
shown). We propose that the injection of Dox^lipo-
somes^OVA, at doses of doxorubicin which are toxic
for macrophages, will lead to the extensive death of
the mature macrophages, the fraction of large size
cells described by Daemen [19,20], and that T-cell
cross-priming may occur. We believe that in the sec-
ond round of injections, immature dendritic cells and
macrophages may become involved and may e⁄-
ciently present OVA antigens derived from the pro-
cessing of internalized apoptotic bodies to class II
restricted T-cells. The T-cell activation resulting
from the processing of phagocytosed apoptotic cells
by immature phagocytic cells yields antigens which
will be recognized by antigen-speci¢c CD4 T-cells.
This process is termed ‘T-cell cross-priming’ [37]. In-
deed, cells undergoing apoptosis may elicit an im-
mune response initiated from the interaction among
components of the immune response, CD8 T-cells,
CD4 T- and B-cells, and requires the direct involve-
ment of professional phagocytic cells. However, de-
pending on the dose of Dox^liposomes^OVA, the
number of apoptotic cells may be di¡erent and either
T-cell activation or T-cell blockade can result. Fol-
lowing extensive killing of macrophages after injec-
tions of high dose of Dox^liposomes, immature den-
dritic cells may be overwhelmed by apoptotic cells
which may consequently result in a functional and
speci¢c T-cell blockade that will a¡ect the immune
response against the associated antigen. Experiments
looking at the e¡ect of doxorubicin on speci¢c T-cell
activation in mice injected with high doses of doxo-
rubicin entrapped in liposomes with conjugated OVA
are currently ongoing to verify this hypothesis. Sev-
eral considerations may explain the failure of Dox^
liposomes^OVA to elicit a speci¢c immune response.
Processing of the dying cells by phagocytic cells may
lead to the production and presentation of an altered
epitope repertoire [38]. The engulfment of apoptotic
cells by macrophages/dendritic cells does not trigger
activation and up-regulation of MHC and co-stimu-
latory molecules. Finally, macrophages, upon engulf-
ment of apoptotic cells may release immunomodula-
tory factors, such as anti-in£ammatory IL-10 and
TGF-L [39,40]. Indeed, in a recent investigation on
the immunogenic potential of apoptotic cells in vivo,
it was found that IL-10 was consistently released in
the serum of animals immunized with apoptotic tu-
mor cells [38]. Furthermore, injection of apoptotic
cells signi¢cantly impaired cell-mediated immune re-
sponses in mice as measured by delayed-type hyper-
sensitivity reactions. Our results suggest that a prev-
alence of professional phagocytes may favor antigen
sequestration and paralysis of the immune response
via release of soluble factors. Their ability to cross
prime T-lymphocytes can be a¡ected by the fact that
apoptotic cell clearance by phagocytic cells is associ-
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ated with the production of immunoregulatory fac-
tors such as IL-10.
In summary, the results presented here show that
doses of liposome-encapsulated doxorubicin as low
as 2 mg/kg can be repeatedly administered with sur-
face-coupled ovalbumin without the generation of a
humoral immune response. Low doses of doxorubi-
cin selectively inhibit humoral immunity, while high
drug doses induce general immune suppression. The
results presented here suggest that encapsulation of
doxorubicin, and therefore possibly other cytotoxic
drugs, could be successfully used in targeted lipo-
some-delivery systems due to their inhibitory e¡ects
on target molecule immunogenicity. Initial studies
also suggest that similar systems could be potentially
useful in the development of antigen selective im-
mune suppression, a possibility that warrants further
investigation.
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